Elinzanetant Shows Promise in Managing Vasomotor Symptoms for Menopausal and Breast Cancer Patients
Discover how Bayer's elinzanetant offers promising relief for vasomotor symptoms in menopausal and breast cancer patients, with significant trial results showing reduced hot flashes and improved sleep.
FDA Issues GBS Warning for GSK and Pfizer RSV Vaccines
The FDA's issues a new warning on GSK and Pfizer's RSV vaccines regarding a potential risk of Guillain-Barré syndrome.
Metsera’s MET-097i: A Promising Advancement in Long-Acting Obesity Treatment
Metsera announces promising obesity therapy, improving upon current incretin-based drugs by offering longer-lasting effects and fewer side effects, potentially transforming weight management and heart health strategies.
FDA Announces Guidelines for Implementing Artificial Intelligence in Drug Development
The FDA announces their first official guideline on the implementation of artificial intelligence in the drug development process.
TEV’749: Teva’s Controlled-Release Schizophrenia Treatment in Phase 3 Trials
In an effort to further address CNS and mental health conditions, Teva Pharmaceuticals is developing TEV'749, a long-acting formulation of olanzapine.
Bipartisan Bill Introduces Key Healthcare Reforms to Enhance Transparency and Access
On December 18, 2024, U.S. lawmakers unveiled a bipartisan stopgap funding bill to finance the federal government through March, incorporating significant healthcare provisions.
Zimmer Biomet Gains FDA Clearance for Osseofit Stemless Shoulder Implant
Zimmer Biomet's Osseofit stemless shoulder implant receives FDA clearance, offering a bone-preserving solution for total shoulder replacements. Designed to match the humeral anatomy, the implant aims to enhance surgical outcomes and workflow efficiency, particularly in ambulatory surgery centers.
The Transformative Role of AI in Clinical Trials and Drug Development
Discover how AI is revolutionizing clinical trials and drug development, enhancing efficiency, accuracy, and patient care, while facing adoption challenges in the biopharma industry.
FDA Identifies New Safety Concerns for Ocaliva in Treating Rare Liver Disease
The FDA has reported additional safety risks linked to Ocaliva, a drug for primary biliary cholangitis, citing serious liver injuries in patients. This marks another setback for the drug, originally poised as a blockbuster.
Cellenkos’ CK0804 Shows Promise in Phase 1b Myelofibrosis Trial
Cellenkos' CK0804 T-regulatory cell therapy demonstrates safety and efficacy in phase 1b trial for myelofibrosis. Encouraging outcomes include reduced spleen volume, symptom relief, and improved transfusion needs.
Impact of Shift Changes on Triage Accuracy and Patient Care in Emergency Departments
A study of over 2 million emergency department records reveals that triage nurses become more lenient during their shifts, leading to lower priority assignments for patients arriving just after shift changes. This results in reduced care levels and increased need for further emergency treatment.
NIH’s TrialGPT: AI’s Potential in Revolutionizing Clinical Trial Recruitment
The NIH has developed TrialGPT, an AI-powered algorithm designed to match patients to suitable clinical trials more efficiently.
Breakthrough Injection Offers Hope for Asthma and COPD Attacks
A new injection for asthma and COPD attacks shows promise in reducing the need for further treatment by 30%, potentially revolutionizing patient care and improving global health outcomes.
High Out-of-Pocket Costs Leave Nearly a Quarter of Americans Underinsured, Survey Reveals
A recent Commonwealth Fund survey highlights that 23% of working-age Americans are underinsured, facing high out-of-pocket costs that hinder access to necessary healthcare. The report also notes significant coverage gaps, with many delaying care due to cost barriers.
Merck’s Winrevair Shows Promise in Expanding Cardiovascular Treatment Market
Merck's cardiovascular drug Winrevair demonstrates significant efficacy in treating pulmonary arterial hypertension, potentially expanding its market presence as Keytruda faces patent expiration. Recent ZENITH trial results indicate promising outcomes for patients with severe lung hypertension.
Recognizing Patients and Partners: The Rise of Patient Empowerment
Discover how patient empowerment is transforming clinical research. Learn about evolving regulatory guidelines, technology integration, and community-based approaches that enhance patient involvement and decision-making in trials.
Abbott’s Initiative for Enhancing Diversity in Clinical Trials
Abbott's Diversity in Clinical Trials initiative outlines strategies to enhance inclusivity in clinical research, addressing barriers to participation and fostering partnerships to ensure diverse patient representation.
Enhancing Diversity in Clinical Trials: The Role of Systematic Literature Reviews in FDA’s DEI Initiatives
Systematic literature reviews (SLRs) play a crucial role in shaping inclusive and diverse clinical trials by offering insights into the demographics and health factors of various patient populations. Aligned with the FDA’s DEI initiatives, SLRs help clinical trial sponsors understand the diversity of treatment populations, ensuring trials are representative and addressing potential biases in healthcare research. By drawing on comprehensive data, SLRs support the FDA’s goals for more equitable and generalizable clinical trials.
UPDATE: Eli Lilly Joins J&J in Challenging Federal 340B Drug Discount Program in Court
Eli Lilly and Johnson & Johnson have filed lawsuits against the U.S. government over the administration of the 340B drug discount program, seeking to implement rebate systems for hospitals instead of providing upfront drug discounts. The legal actions highlight ongoing tensions between pharmaceutical companies and healthcare providers over program costs and compliance.
Market Access “Back to School”: How to Plan and Prioritize Your 2025 Projects
Plan for 2025 in biopharma with insights on adapting to market changes, leveraging digital tools, and engaging key opinion leaders. Ensure guideline inclusion and stay competitive with strategic positioning. Use this checklist to prioritize initiatives for the evolving landscape.
Advancing Precision in Long COVID Research Through Enhanced Phenotyping
Discover how a novel precision phenotyping algorithm improves the identification of long COVID patients, enhancing research accuracy and reducing demographic biases in cohort studies.
Bridging Data and Trust in Clinical Trial Recruitment
Patient recruitment in clinical trials faces significant challenges, often failing to meet enrollment timelines despite advancements in data-driven strategies. The most successful recruitment approaches integrate data insights with trust-building efforts, tailored to the specific needs of each trial to enhance efficiency and inclusivity.
Johnson & Johnson Challenges Federal Government Over 340B Rebate Plan
Johnson & Johnson has filed a lawsuit against the Biden administration, seeking to implement a rebate model for the 340B drug discount program. The pharmaceutical giant aims to replace upfront discounts with after-the-fact rebates, a move met with opposition from hospitals and federal regulators.
Senate Scrutiny on Pfizer and Lilly’s Telehealth Platforms Over Potential Anti-Kickback Violations
Pfizer and Eli Lilly face Senate inquiries over their telehealth prescription platforms amid concerns of potential violations of anti-kickback rules and inappropriate prescribing practices. Lawmakers are demanding clarity on these direct-to-patient programs.
Making Real-World Data Research-Ready
With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data. This episode of tHEORetically Speaking features Jeff Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.
